SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion

May 21, 2018 at 13:56 PM EDT

Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday ...